Clinical Trial Overview
Clinical Trial Finder
If you have diabetes and are overweight, you can have silent liver disease too
Learn about fatty liver disease and NASH, and see if you may qualify for a clinical trial.
About NASH
If you have diabetes or struggle with your weight, you may have fatty liver disease. A severe form of fatty liver disease, called nonalcoholic steatohepatitis (NASH), often has no symptoms but can cause significant damage to your liver if not diagnosed early.
About the Clinical Trial
The MK-3655 Clinical Trial is evaluating the safety and effectiveness of MK-3655, an investigational medication for people with NASH. This trial will test MK-3655 compared to placebo. A placebo looks like the study medication but contains no active ingredient.
You may be able to participate if you: *
- Are a male or postmenopausal female, 18 to 80 years of age [in Japan: 20 to 80 years of age]
- Have NASH confirmed by a liver biopsy
- Do not have type 2 diabetes OR have type 2 diabetes that is well controlled by diet or a stable dose of diabetes medication
- Have had a stable weight for at least 3 months
If you qualify and decide to participate:
- Your liver and your overall health will be monitored closely by an experienced study team
- You will receive the investigational medication and study-related doctor visits at no charge
- The information gathered may help advance medical knowledge about NASH and may improve patient care in the future
- Participation is voluntary and you are free to withdraw from the study at any time. Your privacy will be maintained throughout the clinical trial
To learn more, including the possible risks and benefits of participation, visit NASH3655Study.com.
For a copy of this information, you can download this flyer.
*There may be additional requirements to participate. The study doctor can provide you with more information. Additional potential risks and benefits will be fully described to you by your study team.